CYP4A30B Activators
CYP4A30B, a cytochrome P450 enzyme, is involved in 16-hydroxypalmitate dehydrogenase and monooxygenase activities, crucial for fatty acid metabolism and icosanoid biosynthesis. Predicted to function in various cellular compartments, its role in kidney development and association with hypertension underscores its physiological significance. Activation of CYP4A30B is orchestrated by a repertoire of chemicals, either directly or indirectly modulating its enzymatic activities. Direct activators include Wy-14643, GW7647, and Clofibrate, which act through peroxisome proliferator-activated receptor alpha (PPARα) activation, leading to increased transcription and elevated enzyme levels. Leukotriene B4 (LTB4) and 20-Hydroxyeicosatetraenoic Acid (20-HETE) directly stimulate CYP4A30B by acting as substrates, promoting enzymatic activity in the icosanoid biosynthetic process.
Indirect activators encompass Tazarotene, an RAR modulator, and epoxide hydrolase inhibitors, preventing the degradation of epoxyeicosatrienoic acids (EETs). Acetaminophen induces cytochrome P450 enzymes, indirectly activating CYP4A30B and enhancing fatty acid metabolism. Thiazolidinediones (TZDs) activate CYP4A30B through peroxisome proliferator-activated receptor gamma (PPARγ) modulation. Prostaglandin E2 (PGE2) directly stimulates CYP4A30B as a substrate, contributing to an autoregulatory loop in the metabolism of fatty acids. Understanding the specific pathways and molecules influencing CYP4A30B activation is crucial for unraveling its role in fatty acid metabolism and icosanoid biosynthesis. The identified chemicals provide valuable insights into the diverse mechanisms underlying the regulation of CYP4A30B, paving the way for further research into its functional significance in kidney development and its implications in hypertension.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
WY 14643 | 50892-23-4 | sc-203314 | 50 mg | $136.00 | 7 | |
Direct activator of CYP4A30B through peroxisome proliferator-activated receptor alpha (PPARα) activation. Wy-14643 binding to PPARα induces its translocation into the nucleus, leading to increased transcription of CYP4A30B. This results in elevated enzyme levels and enhanced 16-hydroxypalmitate dehydrogenase and monooxygenase activities. | ||||||
GW 7647 | 265129-71-3 | sc-203068A sc-203068 sc-203068B sc-203068C | 1 mg 5 mg 10 mg 25 mg | $49.00 $170.00 $267.00 $661.00 | 6 | |
Directly activates CYP4A30B by binding to peroxisome proliferator-activated receptor alpha (PPARα). GW7647-activated PPARα translocates into the nucleus, leading to increased transcription of CYP4A30B. This results in elevated enzyme levels and enhanced 16-hydroxypalmitate dehydrogenase and monooxygenase activities. | ||||||
Clofibrate | 637-07-0 | sc-200721 | 1 g | $33.00 | ||
Activates CYP4A30B by binding to peroxisome proliferator-activated receptor alpha (PPARα). Clofibrate-activated PPARα translocates into the nucleus, leading to increased transcription of CYP4A30B. This results in elevated enzyme levels and enhanced 16-hydroxypalmitate dehydrogenase and monooxygenase activities. | ||||||
LTB4 (Leukotriene B4) | 71160-24-2 | sc-201043 | 50 µg | $374.00 | 4 | |
Directly stimulates CYP4A30B by acting as a substrate. LTB4 is metabolized by CYP4A30B in the icosanoid biosynthetic process, and its binding to the enzyme's active site promotes enzymatic activity. This interaction serves as an autoregulatory mechanism, directly activating CYP4A30B in the metabolism of fatty acids. | ||||||
Fenofibrate | 49562-28-9 | sc-204751 | 5 g | $41.00 | 9 | |
Activates CYP4A30B through peroxisome proliferator-activated receptor alpha (PPARα) activation. Fenofibrate binding to PPARα induces its translocation into the nucleus, leading to increased transcription of CYP4A30B. This results in elevated enzyme levels and enhanced 16-hydroxypalmitate dehydrogenase and monooxygenase activities. | ||||||
Tazarotene | 118292-40-3 | sc-220193 | 10 mg | $103.00 | ||
Acts as an indirect activator of CYP4A30B by modulating retinoic acid receptor (RAR) signaling. Tazarotene binds to RAR, promoting its interaction with retinoid X receptor (RXR). This heterodimer then binds to retinoic acid response elements in the CYP4A30B promoter, upregulating gene expression and subsequently increasing enzyme activity. | ||||||
Acetaminophen | 103-90-2 | sc-203425 sc-203425A sc-203425B | 25 g 100 g 500 g | $41.00 $61.00 $194.00 | 11 | |
Indirectly activates CYP4A30B by inducing cytochrome P450 enzymes. Acetaminophen metabolism generates reactive intermediates that stimulate various P450 enzymes, including CYP4A30B. This indirect activation enhances the icosanoid biosynthetic process and monooxygenase activity, contributing to increased fatty acid metabolism. | ||||||
PGE2 | 363-24-6 | sc-201225 sc-201225C sc-201225A sc-201225B | 1 mg 5 mg 10 mg 50 mg | $57.00 $159.00 $275.00 $678.00 | 37 | |
Directly stimulates CYP4A30B by acting as a substrate. PGE2 is metabolized by CYP4A30B in the icosanoid biosynthetic process, and its binding to the enzyme's active site promotes enzymatic activity. This substrate-specific interaction serves as an autoregulatory mechanism, directly activating CYP4A30B in the metabolism of fatty acids. | ||||||